Anti-PD-1 treatment in vitro with a CT-011 antibody (however, its specificity for PD-1 has been questioned) enhanced natural killer cell trafficking, immune complex formation, and cytotoxicity against PD-L1-bearing multiple myeloma cells (166). The gene discussed is CD274; the disease is plasma cell myeloma.